EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Anna M Varghese, Maria A Perry, Joanne F Chou, Subhiksha Nandakumar, Daniel Muldoon, Amanda Erakky, Amanda Zucker, Christopher Fong, Miika Mehine, Bastien Nguyen, Olca Basturk, Fiyinfolu Balogun und 17 weitere

Nature Medicine · 2025-02 · 31 (2) · 466-477

DOI: 10.1038/s41591-024-03362-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature Medicine, online erschienen am 03.01.2025. Verfasst von Anna M Varghese und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Mutation, Adenocarcinoma. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nearly all pancreatic adenocarcinomas (PDAC) are genomically characterized by KRAS exon 2 mutations. Most patients with PDAC present with advanced disease and are treated with cytotoxic therapy. Genomic biomarkers prognostic of disease outcomes have been challenging to identify. Herein leveraging a cohort of 2,336 patients spanning all disease stages, we characterize the genomic and clinical correlates of outcomes in PDAC. We show that a genomic subtype of KRAS wild-type tumors is associated with early disease onset, distinct somatic and germline features, and significantly better overall survival. Allelic imbalances at the KRAS locus are widespread. KRAS mutant allele dosage gains, observed in one in five (20%) KRAS-mutated diploid tumors, are correlated with advanced disease and demonstrate prognostic potential across disease stages. With the rapidly expanding landscape of KRAS targeting, our findings have potential implications for clinical practice and for understanding de novo and acquired resistance to RAS therapeutics. Analyses of clinical and genomic data from a cohort of 2,336 patients with pancreatic adenocarcinoma find that KRAS dosage gains are a hallmark of disease progression and are predictive of poor outcomes across different disease stages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsProto-Oncogene Proteins p21(ras)MutationAdenocarcinomaCarcinoma, Pancreatic DuctalHumansPrognosisMaleFemaleMiddle AgedAgedGene Dosage

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.

Förderung

  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)

Zitieren

APA

Varghese, A. M., Perry, M. A., Chou, J. F., Nandakumar, S., Muldoon, D., Erakky, A., Zucker, A., Fong, C., Mehine, M., Nguyen, B., Basturk, O., Balogun, F., Kelsen, D. P., Brannon, A. R., Mandelker, D., Vakiani, E., Park, W., Yu, K. H., Stadler, Z. K., …, & O'Reilly, E. M. (2025). Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nature Medicine, 31(2), 466-477. https://doi.org/10.1038/s41591-024-03362-3

Vancouver

Varghese AM, Perry MA, Chou JF, Nandakumar S, Muldoon D, Erakky A, et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nature Medicine. 2025;31(2):466-477. doi:10.1038/s41591-024-03362-3

BibTeX
@article{Varghese2025,
  author = {Varghese, Anna M and Perry, Maria A and Chou, Joanne F and Nandakumar, Subhiksha and Muldoon, Daniel and Erakky, Amanda and Zucker, Amanda and Fong, Christopher and Mehine, Miika and Nguyen, Bastien and Basturk, Olca and Balogun, Fiyinfolu and Kelsen, David P and Brannon, A Rose and Mandelker, Diana and Vakiani, Efsevia and Park, Wungki and Yu, Kenneth H and Stadler, Zsofia K and Schattner, Mark A and Jarnagin, William R and Wei, Alice C and Chakravarty, Debyani and Capanu, Marinela and Schultz, Nikolaus and Berger, Michael F and Iacobuzio-Donahue, Christine A and Bandlamudi, Chaitanya and O'Reilly, Eileen M},
  title = {Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival},
  journal = {Nature Medicine},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {466--477},
  doi = {10.1038/s41591-024-03362-3}
}
Kostenlos starten →